Original site: www.cdc.gov/blood-clots/data-research/facts-stats/index.html RestoredCDC.org is an independent project and is not affiliated with, endorsed by, or associated with the Centers for Disease Control and Prevention (CDC) or any government entity. The CDC provides information free of change at CDC.gov. Note the following: 1) Due to archival on January 6, 2025, no information on recent outbreaks is available. 2) Videos have not been restored. 3) Use of this site implies acceptance of this disclaimer.
Up to 900,000 people in the United States are affected by venous thromboembolism (VTE, a blood clot), each year
People are at particularly high risk for VTE during or just after a hospitalization (with or without surgery), during cancer treatment, and during or just after pregnancy
An estimated 60,000-100,000 Americans die of VTE each year and many others have long-term complications from a VTE
Incidence and prevalence
Venous thromboembolism (VTE) affects all types of people.
Venous thromboembolism (VTE) refers to blood clots in the veins. It includes both deep vein thrombosis (DVT, blood clot in the deep veins, most commonly in the legs) and pulmonary embolism (PE, blood clot in the lungs).
The precise number of people affected by either a DVT or PE is unknown, although as many as 900,000 people could be affected each year in the United States.
Sudden death is the first symptom in about one-quarter (25%) of people who have a PE.
An estimated 60,000-100,000 Americans die of VTE each year.
Healthcare-associated VTE
More than a third of VTE cases diagnosed each year are related to a recent hospitalization and most of these do not occur until after discharge.
VTE is a leading cause of preventable hospital death in the United States.
VTE is the fifth most frequent reason for unplanned hospital readmissions after surgery, overall, and the third most frequent among patients undergoing total hip or knee joint replacement.
As many as 70% of cases of healthcare-associated VTE are preventable through measures such as use of anticoagulant medications or compression stockings. Yet fewer than half of hospital patients receive these measures.
Cancer and VTE
An estimated one in five cases of VTE are related to cancer and its treatment.
The risk is greatest in the first few months after a cancer diagnosis, the time when treatment generally occurs.
Among people with cancer, survival rates are lower for people who also have a VTE.
Pregnancy and VTE
Women are five times more likely to experience a VTE during pregnancy, childbirth, or the 3-month period after delivery.
PE is one of the most common causes of pregnancy-related death in the United States.
Complications
One-third (about 33%) of people with a VTE will have a recurrence within 10 years.
Among people who have had a DVT, one third to one half will have long-term complications (post-thrombotic syndrome) such as swelling, pain, discoloration, and scaling in the affected limb.
Chronic thromboembolic pulmonary hypertension is a complication that can happen after a PE with a large clot. It can stop blood from reaching the lungs and can be fatal.